Clinical Trials Sponsored by Accera, Inc.

Total 35918 results

University of Florida
Access Pharmaceuticals, Inc.

Completed

Patient Comfort With Vascular Closure

Vascular Closure

United States
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) (BALANCE)

Familial Chylomicronemia Syndrome

United States, Israel, Spain, Italy, United Kingdom, Netherlands, Canada, Hungary, Sweden, France, Norway, Portugal, Slovakia
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Cardiovascular Diseases | Hypertriglyceridemia

United States, Canada
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Abnormalities, Cardiovascular

United States
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics

Completed

Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

Elevated Triglycerides (TG)

Canada
University of Texas Southwestern Medical Center
Acera Surgical, Inc.

Withdrawn

RCT to Compare Restrata and NPWT to Heal Complex DFUs

Diabetic Wound

United States
Church & Dwight Company, Inc.
Essential Access Health

Completed

Synthetic Male Condom Slippage-Breakage Study

Sexually Transmitted Diseases | Contraceptive

United States
Accare

Not yet recruiting

First Evaluation of COMET-Y (COMET-Y)

Quality of Life | Self Esteem
Accare

Not yet recruiting

One Session Virtual Reality During Ongoing Treatment for Anxiety: Feasibility in Children and Adolescents

Anxiety Disorders | Social Anxiety Disorder | Exposure
Accare

Recruiting

Brief Parent Training for Children With Behavioral Difficulties in Primary Care Settings (PAINT-POH)

Behavioral Difficulties

Netherlands
Accare

Recruiting

HANDS-ON: a Personalized, Brief and Intensive Exposure-based Intervention for Youth With Persistent Anxiety or OCD

Obsessive-Compulsive Disorder | Anxiety Disorders | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in Adolescence

Netherlands
SQ Innovation, Inc.
Accel Clinical Services

Completed

Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure

Heart Failure

United States
Invivyd, Inc.
In Expanded Access, treating physicians are the Sponsors

No longer available

Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments

COVID-19
Clera Inc.
University Health Network, Toronto

Completed

Efficacy Study of CLR3001 in Depression

Depression

Canada
Accuray Incorporated

Completed

CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

Prostatic Neoplasms | Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Prostatic Cancer

United States
Accuray Incorporated

Completed

CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution

Prostatic Neoplasms | Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Prostatic Cancer

United States
Lycera Corp.

Completed

Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer

Cancer

United States
Lycera Corp.

Completed

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

Psoriasis

United States
Lycera Corp.

Completed

Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis

Ulcerative Colitis

Hungary
Aegera Therapeutics

Terminated

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

Human Mammary Carcinoma

United States
Aegera Therapeutics

Terminated

Study of XIAP Antisense for Advanced Cancers

Advanced Cancer

United Kingdom
Adhera Health, Inc.
Hospital Universitario Virgen Macarena

Completed

SENSING-AI in Patients With Long COVID (SENSING-AI) (SENSING-AI)

Post-acute COVID-19 Syndrome

Spain
M.D. Anderson Cancer Center
Access Pharmaceuticals, Inc.

Completed

4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies

Leukemia

United States
Access Pharmaceuticals, Inc.
Advanced Clinical Research Services, LLC

Completed

Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

Oral Mucositis

United States
Kancera AB

Terminated

KAND567 Versus Placebo in Subjects Hospitalized With COVID-19

Covid19

Denmark, Sweden
Lycera Corp.

Unknown

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Lycera Corp.

Completed

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Colitis, Ulcerative

United States, Czechia, Hungary, Netherlands, Poland, Serbia, Canada
Aegera Therapeutics

Terminated

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Leukemia

United States, Canada, Germany
Aegera Therapeutics

Completed

Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy

Chronic Pain | Diabetic Peripheral Neuropathy

United States, Canada, Bulgaria, Romania
Aegera Therapeutics

Completed

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

Leukemia, Myelomonocytic, Acute

United States, Canada
Aegera Therapeutics

Terminated

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

Carcinoma | Pancreas

United States
ACEA Therapeutics, Inc.
Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Unknown

Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States
Acerta Pharma BV
Acerta Pharma, LLC

Completed

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Multiple Myeloma (MM)

United States, United Kingdom
Kancera AB

Completed

Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567

Healthy

Finland
Lycera Corp.

Terminated

Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Colitis, Ulcerative

United States, Czechia, Hungary, Netherlands, Poland, Serbia
Aegera Therapeutics

Terminated

A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (ElevateTN)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, Belgium, Brazil, Poland, United Kingdom, Canada, Germany, Australia, Israel, Hungary, France, New Zealand, Chile, Lithuania, Sweden, Colombia
Acerta Pharma BV

Active, not recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Chronic Lymphocytic Leukemia

Austria, Italy, Spain, United Kingdom, Belgium, Taiwan, France, Korea, Republic of, Hungary, United States, Ukraine, Canada, Australia, Germany, Israel, Czechia, Russian Federation, Slovakia, Poland, Bulgaria, New Zealand, Sweden, C... and more
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Acerta Pharma BV

Active, not recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Acerta Pharma BV

Active, not recruiting

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

United States, United Kingdom
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Waldenström Macroglobulinemia (WM)

Spain, United States, United Kingdom, France, Italy, Greece, Netherlands
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

Healthy Volunteers

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

Hepatic Insufficiency

United States
Acerta Pharma BV

Terminated

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
TeneoFour Inc.
Novotech (Australia) Pty Limited

Completed

A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers

Healthy Volunteer

Australia

Clinical Trials Sponsored by Accera, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations